BUZZ-Replimune surges after report FDA chief Makary may be ousted

Replimune

Replimune

REPL

0.00

** Shares of biotech firm Replimune REPL.O rise 16.47% to $3.89

** U.S. President Donald Trump is planning to fire U.S. Food and Drug Administration Commissioner Marty Makary, the Wall Street Journal reports, citing people familiar with the matter

** Makary on Tuesday defended the regulator's decision to not approve REPL's drug, Tudriqev for advanced skin cancer

** Last month, the health regulator declined to approve the drug for the second time

** Including session's move, REPL down ~60% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.